Rituximab in refractory and relapsed dermatomyositis and polymyositis: comment on the article by Oddis et al.


To the Editor: In the 44-week Rituximab in Myositis (RIM) study, an 83% success rate was achieved in a well-defined cohort of patients with treatment-refractory adult polymyositis (PM) or adult or juvenile dermatomyositis (DM) (1). In her editorial, Dr. de Visser noted concerns regarding the current classification criteria for these diseases and the need… (More)
DOI: 10.1002/art.38018


1 Figure or Table